undamentalytics Newsletter
Sign in

Arrowhead Pharmaceuticals, Inc. revenue

Arrowhead Pharmaceuticals, Inc.'s revenue was $829m in fiscal 2025, up 23258.2% on the year before. Since fiscal 2011 ($296,139) it has grown at a compound 76.3% a year. Over the last twelve months it was $669m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Sept 20112012Sept 20122013Sept 20132014Sept 20142015Sept 20152016Sept 20162017Sept 20172018Sept 20182019Sept 20192020Sept 20202021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Revenue0000003116169881382432414829669
Growth on the year before—−50.4%+97.6%−39.7%+118.3%−58.6%+>999%−48.6%+945.7%−47.9%+57.2%+75.9%−1.0%−98.5%+>999%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Arrowhead Pharmaceuticals, Inc. $669m 16.8% 37.7%
Nurix Therapeutics, Inc. $702m 738.8% 117.1%
Ultragenyx Pharmaceutical Inc. $717m 17.5% 21.2%
Mirum Pharmaceuticals, Inc. $618m 44.0% 74.8%
Tarsus Pharmaceuticals, Inc. $606m 105.2% 264.7%
TG Therapeutics, Inc. $800m 76.1% 221.5%

Compare with peers

Head to head: ARWR vs NRIXARWR vs RAREARWR vs MIRMARWR vs TARS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arrowhead Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arrowhead Pharmaceuticals, Inc.